The cancer cell lines in the Oncolines™ panel are from diverse tumour tissue origin and have been characterized with regard to the mutation status of more than hundred cancer-causing genes and by the expression of more than eighteen thousand genes. The drug sensitivity of the cell lines is determined in cell proliferation assays and correlated to the cancer gene mutation status of the cell lines, yielding novel candidate drug sensitivity biomarkers as shown by (Uitdehaag et al. 2019).
These biomarkers are used as selection markers for patient stratification (Zaman et al., 2017), while the drug sensitivity fingerprint of compounds in the entire Oncolines™ cell panel is used for comparative analyses with other anti-cancer agents, described by (Uitdehaag et al. 2016), and for mechanism-of-action studies (Libouban et al., 2017). The Oncolines™ cell lines are also the basis of drug combination screens, as described by (Uitdehaag et al. 2015).
NTRC has a commercial license from the American Type Culture Collection (ATCC) for the 102 cell lines in the current panel. Clients of NTRC order either full panel profiling studies or cherry pick cell lines from the panel based on specific characteristics, such as tumour origin or expression of certain cancer gene mutations.